Loncar Biotech ETFs invest in innovators. Hear straight from CEOs about the companies our ETFs support.
Zai Lab — CHNA
We believe with China’s talent pool, with China’s development of the whole biotech ecosystem, China is going to be the future source of innovation for the global life sciences industry." − Samantha Du, Ph.D. Chairman & CEO, Zai Lab
Cellectis — CNCR
Gene editing is a paradigm shift in the field of cell therapy, immuno-oncology, and medicine in general and that’s where Cellectis is trying to make the point." − André Choulika Chairman & CEO, CEllectis
Adaptimmune — CNCR
I don’t think anything could be more exciting than trying to have a major effect on cancer patients. It’s a privilege, to be honest, to be involved in such an exciting field." − James Noble CEO, Adaptimmune